Autoimmune events during interferon beta-1b treatment for multiple sclerosis

Area of Science:

• Immunology
• Neurology
• Endocrinology

Background:

• Autoimmune events are rarely reported in relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta-1b (IFNB).
• Immunologic abnormalities are common in multiple sclerosis, potentially increasing the risk of autoimmune events during IFNB treatment.

Purpose of the Study:

• To prospectively monitor autoimmune events in RRMS patients treated with IFNB.
• To assess the frequency and impact of autoantibodies and organ-specific/non-organ-specific autoimmune events during IFNB therapy.

Main Methods:

• Prospective two-year follow-up of 40 RRMS patients on IFNB and 21 untreated controls.
• Serial monitoring of thyroid and liver function, and 12 types of autoantibodies (autoAbs).

Main Results:

• Autoantibodies (anti-nuclear, smooth muscle, thyroid) were detected in 13 IFNB-treated patients, compared to controls.
• Thyroid dysfunction occurred in three IFNB-treated patients, particularly women with a history of thyroid disease.
• Liver function alterations were observed in 17 IFNB-treated patients, often transient and associated with non-organ-specific autoAbs.

Conclusions:

• Interferon beta-1b treatment for MS can be associated with various autoimmune events.
• Close monitoring of thyroid function, liver function, and autoantibody levels is crucial for patients undergoing IFNB therapy.
• Autoimmune thyroid dysfunction can be managed without interrupting IFNB treatment, and liver function alterations are typically transient.